SL Science Announces Successful Exhibition of Breakthrough Brain Cancer Therapy Research at the 2026 World Congress of Basic and Clinical Pharmacology
SL Science presented promising preclinical research at the 2026 World Congress of Basic and Clinical Pharmacology, highlighting the efficacy of its gamma delta T-cell platform in treating glioblastoma. The study data showed complete tumor eradication by day 26 post-treatment at an 8:1 cell-to-cancer ratio, with a clean safety profile and no adverse effects observed.
Key figures
- Phase Of Trial
- preclinical
- Cell ratio
- 8:1
- Tumor elimination day
- 26
AI analysis
Red flags2 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.